1. Home
  2. ARCT vs ENTX Comparison

ARCT vs ENTX Comparison

Compare ARCT & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arcturus Therapeutics Holdings Inc.

ARCT

Arcturus Therapeutics Holdings Inc.

HOLD

Current Price

$15.82

Market Cap

163.4M

Sector

Health Care

ML Signal

HOLD

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

HOLD

Current Price

$3.00

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARCT
ENTX
Founded
2013
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
163.4M
147.4M
IPO Year
2019
2015

Fundamental Metrics

Financial Performance
Metric
ARCT
ENTX
Price
$15.82
$3.00
Analyst Decision
Buy
Strong Buy
Analyst Count
10
1
Target Price
$24.11
$9.00
AVG Volume (30 Days)
1.4M
324.6K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
20.00
N/A
EPS
N/A
0.22
Revenue
$82,031,000.00
$42,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$12.77
N/A
P/E Ratio
N/A
$13.39
Revenue Growth
N/A
N/A
52 Week Low
$5.50
$0.91
52 Week High
$24.14
$4.20

Technical Indicators

Market Signals
Indicator
ARCT
ENTX
Relative Strength Index (RSI) 70.15 52.24
Support Level $6.47 $2.66
Resistance Level N/A $3.10
Average True Range (ATR) 1.60 0.23
MACD 0.35 -0.07
Stochastic Oscillator 76.36 19.09

Price Performance

Historical Comparison
ARCT
ENTX

About ARCT Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: